Coronado Biosciences to Present at the Citi 2012 Global Health Care Conference
February 23, 2012 06:59 ET
|
Coronado Biosciences
BURLINGTON, Mass., Feb. 23, 2012 (GLOBE NEWSWIRE) -- Coronado Biosciences, Inc. (Nasdaq:CNDO), a biopharmaceutical company focused on the development of novel immunotherapy agents for the treatment of...
Coronado Biosciences Appoints Lucy Lu, M.D. as Executive Vice President and Chief Financial Officer
February 22, 2012 16:01 ET
|
Coronado Biosciences
BURLINGTON, Mass., Feb. 22, 2012 (GLOBE NEWSWIRE) -- Coronado Biosciences, Inc. (Nasdaq:CNDO), a biopharmaceutical company focused on the development of novel immunotherapy agents for the treatment of...
Coronado Biosciences Announces IND Submission for CNDO-109 for the Treatment of Relapsed Acute Myeloid Leukemia
February 14, 2012 06:59 ET
|
Coronado Biosciences
BURLINGTON, Mass., Feb. 14, 2012 (GLOBE NEWSWIRE) -- Coronado Biosciences, Inc. (Nasdaq:CNDO), a biopharmaceutical company focused on the development of novel immunotherapy agents for the treatment of...
Coronado Biosciences to Present at the Leerink Swann 2012 Global Healthcare Conference
February 13, 2012 07:30 ET
|
Coronado Biosciences
BURLINGTON, Mass., Feb. 13, 2012 (GLOBE NEWSWIRE) -- Coronado Biosciences, Inc. (Nasdaq:CNDO), a biopharmaceutical company focused on the development of novel immunotherapy agents for the treatment of...
Coronado Biosciences to Present at 30th Annual JP Morgan Healthcare Conference
January 12, 2012 07:30 ET
|
Coronado Biosciences
BURLINGTON, Mass., Jan. 12, 2012 (GLOBE NEWSWIRE) -- Coronado Biosciences, Inc. (Nasdaq:CNDO), a biopharmaceutical company focused on the development of novel immunotherapy agents for the treatment of...
Coronado Biosciences to Present at the Biotech Showcase 2012 Conference
January 06, 2012 08:42 ET
|
Coronado Biosciences
BURLINGTON, Mass., Jan. 6, 2012 (GLOBE NEWSWIRE) -- Coronado Biosciences, Inc. (Nasdaq:CNDO), a biopharmaceutical company focused on the development of novel immunotherapy agents for the treatment of...
Coronado Biosciences Signs Binding Terms of Agreement to Enter Into Collaboration for Development of CNDO-201 for Crohn's Disease With Dr. Falk Pharma and OvaMed
December 22, 2011 14:00 ET
|
Coronado Biosciences
BURLINGTON, Mass., Dec. 22, 2011 (GLOBE NEWSWIRE) -- Coronado Biosciences, Inc. (Nasdaq:CNDO), a biopharmaceutical company focused on the development of novel immunotherapy agents for the treatment of...
Coronado Biosciences Appoints Karin Hehenberger, M.D., Ph.D. as Senior Vice President of Scientific Affairs
December 20, 2011 07:30 ET
|
Coronado Biosciences
BURLINGTON, Mass., Dec. 20, 2011 (GLOBE NEWSWIRE) -- Coronado Biosciences, Inc., (Nasdaq:CNDO), a biopharmaceutical company focused on the development of novel immunotherapy agents for the treatment...
Coronado Biosciences Approved for Listing on NASDAQ
December 15, 2011 14:14 ET
|
Coronado Biosciences
BURLINGTON, Mass., Dec. 15, 2011 (GLOBE NEWSWIRE) -- Coronado Biosciences, Inc., (OTCBB:CNDO), a biopharmaceutical company focused on the development of novel immunotherapy agents for the treatment of...
Coronado Biosciences is Granted First Patent for CNDO-109
December 14, 2011 07:30 ET
|
Coronado Biosciences
BURLINGTON, Mass., Dec. 14, 2011 (GLOBE NEWSWIRE) -- Coronado Biosciences, Inc., (OTCBB:CNDO), a biopharmaceutical company focused on the development of novel immunotherapy agents for the treatment of...